<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00452335</url>
  </required_header>
  <id_info>
    <org_study_id>0211SC-0641</org_study_id>
    <nct_id>NCT00452335</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation</brief_title>
  <official_title>A Multi-center, Open-labeled Study of the Safety, Efficacy, and Pharmacokinetics of Lubiprostone in Pediatric Patients With Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sucampo Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sucampo Pharma Americas, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the safety and efficacy of lubiprostone in a
      pediatric population with constipation, including the pharmacokinetics of lubiprostone, in a
      subset of patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Spontaneous Bowel Movements</measure>
    <time_frame>Week 1</time_frame>
    <description>Gathered as part of the daily electronic diary questions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Spontaneous Bowel Movements</measure>
    <time_frame>Weeks 2, 3, and 4</time_frame>
    <description>Gathered as part of the daily electronic diary questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Fecal Incontinence</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>As part of the daily diary, patients were asked to report the number of fecal incontinence episodes per day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Straining Associated With SBMs</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>Bowel straining assessed based on the following scale: 0 = no straining, 1 = mild straining, 2 = moderate straining, 3 = severe straining, and 4 = very severe straining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool Consistency of SBMs</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>Stool consistency was captured using the Bristol Stool Form Scale: 1 = Separate hard lumps like nuts, 2 = Sausage shaped but lumpy, 3 = Like a sausage but with cracks on surface, 4 = Like a sausage or snake, smooth and soft, 5 = Soft blobs with clear-cut edges, 6 = Fluffy pieces with ragged edges, a mushy stool, and 7 = Watery, no solid pieces.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Bloating</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>Abdominal bloating was assessed based on the following scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal Discomfort</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>Abdominal discomfort was assessed based on the following scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Associated With SBMs</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>Pain associated with SBMs was assessed based on the following scale: 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain, and 4 = very severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constipation Severity</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>Constipation severity was assessed based on the following scale 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Effectiveness</measure>
    <time_frame>Weekly, up to 4 weeks</time_frame>
    <description>Treatment effectiveness was assessed with the following scale: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, and 4 = extremely effective.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>Lubiprostone 12 mcg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lubiprostone 12 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lubiprostone 24 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>12 mcg capsule once daily (QD)</description>
    <arm_group_label>Lubiprostone 12 mcg QD</arm_group_label>
    <other_name>Amitiza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>12 mcg capsule twice daily (BID)</description>
    <arm_group_label>Lubiprostone 12 mcg BID</arm_group_label>
    <other_name>Amitiza®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lubiprostone</intervention_name>
    <description>24 mcg capsule twice daily (BID)</description>
    <arm_group_label>Lubiprostone 24 mcg BID</arm_group_label>
    <other_name>Amitiza®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Less than 18 years of age

          -  Weight of at least 12 kg and capable of swallowing a capsule

          -  Able to refrain from use of medications known to treat or associated with constipation
             symptoms

          -  Stable fiber therapy or ADHD therapy if using such medications

          -  Patient/Caregiver able to complete daily diary

          -  Patient able to use recommended rectal and/or oral rescue medications if needed

        Exclusion Criteria:

          -  Constipation is associated with some medical, anatomic, physical, organic, or other
             condition

          -  Hirschsprung's Disease or Nonretentive Fecal Incontinence

          -  Untreated fecal impactions or impactions requiring digital manipulation

          -  Open gastrointestinal/abdominal surgery or laparoscopic surgery at the investigator
             discretion

          -  Organic bowel disorder, mechanical bowel obstruction, pseudo-obstruction, or
             unexplained weight loss

          -  Uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric
             disorder, other systemic disease, or abnormal laboratory tests at the investigator
             discretion

          -  If female, is currently pregnant or nursing, or plans to become pregnant or nurse
             during the clinical study

          -  Sexually active males and females must utilize acceptable birth control methods

          -  Prior use of lubiprostone, Amitiza, SPI-0211, or RU-0211
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hyman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Pheonix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Pediatric Clinic</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemours Children's Clinic - Pensacola</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Children's Digestive Health</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62708-0787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Human Nutrition, Inc.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHS Hospital Corporation</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Associates of Fairfield, Inc.</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Gastroenterology Associates of Lancaster, Ltd.</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeastern Clinical Research</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jackson Clinic</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2007</study_first_submitted>
  <study_first_submitted_qc>March 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2007</study_first_posted>
  <results_first_submitted>February 16, 2016</results_first_submitted>
  <results_first_submitted_qc>July 12, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2016</results_first_posted>
  <disposition_first_submitted>October 21, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>October 21, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 19, 2010</disposition_first_posted>
  <last_update_submitted>July 12, 2016</last_update_submitted>
  <last_update_submitted_qc>July 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lubiprostone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>127 participants were randomized to study treatment, however only 124 participants received study drug</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>12 mcg QD</title>
          <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
        </group>
        <group group_id="P2">
          <title>12 mcg BID</title>
          <description>Up to 24 adolescents (12–17 years of age) and all children (6–11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
        </group>
        <group group_id="P3">
          <title>24 mcg BID</title>
          <description>Adolescents (12–17 years of age)and children (6–11 years of age) who are ≥36 kg body weight</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="61"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>12 mcg QD</title>
          <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
        </group>
        <group group_id="B2">
          <title>12 mcg BID</title>
          <description>Up to 24 adolescents (12–17 years of age) and all children (6–11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
        </group>
        <group group_id="B3">
          <title>24 mcg BID</title>
          <description>Adolescents (12–17 years of age)and children (6–11 years of age) who are ≥36 kg body weight</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="65"/>
            <count group_id="B3" value="32"/>
            <count group_id="B4" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="1.67"/>
                    <measurement group_id="B2" value="10.3" spread="2.78"/>
                    <measurement group_id="B3" value="13.9" spread="3.00"/>
                    <measurement group_id="B4" value="10.2" spread="3.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Spontaneous Bowel Movements</title>
        <description>Gathered as part of the daily electronic diary questions.</description>
        <time_frame>Week 1</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Spontaneous Bowel Movements</title>
          <description>Gathered as part of the daily electronic diary questions.</description>
          <population>ITT population</population>
          <units>spontaneous bowel movements per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.47" spread="2.68"/>
                    <measurement group_id="O2" value="3.02" spread="2.17"/>
                    <measurement group_id="O3" value="3.84" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Spontaneous Bowel Movements</title>
        <description>Gathered as part of the daily electronic diary questions.</description>
        <time_frame>Weeks 2, 3, and 4</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Spontaneous Bowel Movements</title>
          <description>Gathered as part of the daily electronic diary questions.</description>
          <population>ITT Population</population>
          <units>spontaneous bowel movements per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" spread="2.278"/>
                    <measurement group_id="O2" value="2.59" spread="2.316"/>
                    <measurement group_id="O3" value="3.51" spread="1.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" spread="2.210"/>
                    <measurement group_id="O2" value="2.60" spread="2.006"/>
                    <measurement group_id="O3" value="3.58" spread="2.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="2.130"/>
                    <measurement group_id="O2" value="2.68" spread="2.258"/>
                    <measurement group_id="O3" value="2.99" spread="1.827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Fecal Incontinence</title>
        <description>As part of the daily diary, patients were asked to report the number of fecal incontinence episodes per day.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Fecal Incontinence</title>
          <description>As part of the daily diary, patients were asked to report the number of fecal incontinence episodes per day.</description>
          <population>ITT Population</population>
          <units>episodes of fecal incontinence per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="1.141"/>
                    <measurement group_id="O2" value="0.22" spread="0.489"/>
                    <measurement group_id="O3" value="0.03" spread="0.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.768"/>
                    <measurement group_id="O2" value="0.21" spread="0.446"/>
                    <measurement group_id="O3" value="0.05" spread="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.989"/>
                    <measurement group_id="O2" value="0.16" spread="0.336"/>
                    <measurement group_id="O3" value="0.01" spread="0.060"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="1.168"/>
                    <measurement group_id="O2" value="0.17" spread="0.457"/>
                    <measurement group_id="O3" value="0.02" spread="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Straining Associated With SBMs</title>
        <description>Bowel straining assessed based on the following scale: 0 = no straining, 1 = mild straining, 2 = moderate straining, 3 = severe straining, and 4 = very severe straining.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 Mch BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Straining Associated With SBMs</title>
          <description>Bowel straining assessed based on the following scale: 0 = no straining, 1 = mild straining, 2 = moderate straining, 3 = severe straining, and 4 = very severe straining.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="1.074"/>
                    <measurement group_id="O2" value="1.34" spread="1.001"/>
                    <measurement group_id="O3" value="1.44" spread="0.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.02" spread="1.010"/>
                    <measurement group_id="O2" value="1.22" spread="0.868"/>
                    <measurement group_id="O3" value="1.30" spread="1.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="0.857"/>
                    <measurement group_id="O2" value="1.11" spread="0.809"/>
                    <measurement group_id="O3" value="1.16" spread="1.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.03" spread="0.887"/>
                    <measurement group_id="O2" value="1.31" spread="1.096"/>
                    <measurement group_id="O3" value="0.97" spread="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stool Consistency of SBMs</title>
        <description>Stool consistency was captured using the Bristol Stool Form Scale: 1 = Separate hard lumps like nuts, 2 = Sausage shaped but lumpy, 3 = Like a sausage but with cracks on surface, 4 = Like a sausage or snake, smooth and soft, 5 = Soft blobs with clear-cut edges, 6 = Fluffy pieces with ragged edges, a mushy stool, and 7 = Watery, no solid pieces.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Stool Consistency of SBMs</title>
          <description>Stool consistency was captured using the Bristol Stool Form Scale: 1 = Separate hard lumps like nuts, 2 = Sausage shaped but lumpy, 3 = Like a sausage but with cracks on surface, 4 = Like a sausage or snake, smooth and soft, 5 = Soft blobs with clear-cut edges, 6 = Fluffy pieces with ragged edges, a mushy stool, and 7 = Watery, no solid pieces.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.87" spread="1.197"/>
                    <measurement group_id="O2" value="3.20" spread="1.168"/>
                    <measurement group_id="O3" value="3.14" spread="1.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.09" spread="1.078"/>
                    <measurement group_id="O2" value="2.90" spread="1.198"/>
                    <measurement group_id="O3" value="3.22" spread="1.394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="0.796"/>
                    <measurement group_id="O2" value="3.31" spread="1.121"/>
                    <measurement group_id="O3" value="3.59" spread="1.168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="0.904"/>
                    <measurement group_id="O2" value="2.96" spread="1.160"/>
                    <measurement group_id="O3" value="4.01" spread="1.631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abdominal Bloating</title>
        <description>Abdominal bloating was assessed based on the following scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Bloating</title>
          <description>Abdominal bloating was assessed based on the following scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="0.800"/>
                    <measurement group_id="O2" value="1.39" spread="1.150"/>
                    <measurement group_id="O3" value="1.79" spread="0.876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.929"/>
                    <measurement group_id="O2" value="1.12" spread="1.027"/>
                    <measurement group_id="O3" value="1.16" spread="0.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="1.006"/>
                    <measurement group_id="O2" value="1.00" spread="0.937"/>
                    <measurement group_id="O3" value="1.08" spread="1.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="1.065"/>
                    <measurement group_id="O2" value="1.04" spread="0.865"/>
                    <measurement group_id="O3" value="1.05" spread="0.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abdominal Discomfort</title>
        <description>Abdominal discomfort was assessed based on the following scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Abdominal Discomfort</title>
          <description>Abdominal discomfort was assessed based on the following scale: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="0.800"/>
                    <measurement group_id="O2" value="1.16" spread="1.134"/>
                    <measurement group_id="O3" value="1.43" spread="1.289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" spread="0.929"/>
                    <measurement group_id="O2" value="0.93" spread="0.918"/>
                    <measurement group_id="O3" value="1.20" spread="1.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.795"/>
                    <measurement group_id="O2" value="0.90" spread="0.892"/>
                    <measurement group_id="O3" value="1.17" spread="1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" spread="0.869"/>
                    <measurement group_id="O2" value="1.05" spread="0.915"/>
                    <measurement group_id="O3" value="1.14" spread="1.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Associated With SBMs</title>
        <description>Pain associated with SBMs was assessed based on the following scale: 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain, and 4 = very severe pain.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Associated With SBMs</title>
          <description>Pain associated with SBMs was assessed based on the following scale: 0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain, and 4 = very severe pain.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="1.051"/>
                    <measurement group_id="O2" value="1.13" spread="0.970"/>
                    <measurement group_id="O3" value="1.14" spread="0.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.72" spread="1.009"/>
                    <measurement group_id="O2" value="1.06" spread="0.758"/>
                    <measurement group_id="O3" value="1.10" spread="1.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.929"/>
                    <measurement group_id="O2" value="0.91" spread="0.915"/>
                    <measurement group_id="O3" value="1.01" spread="1.089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.82" spread="0.978"/>
                    <measurement group_id="O2" value="1.07" spread="1.047"/>
                    <measurement group_id="O3" value="1.07" spread="1.298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Constipation Severity</title>
        <description>Constipation severity was assessed based on the following scale 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Constipation Severity</title>
          <description>Constipation severity was assessed based on the following scale 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="1.038"/>
                    <measurement group_id="O2" value="1.69" spread="0.951"/>
                    <measurement group_id="O3" value="1.79" spread="0.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.977"/>
                    <measurement group_id="O2" value="1.43" spread="0.945"/>
                    <measurement group_id="O3" value="1.40" spread="0.816"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" spread="0.908"/>
                    <measurement group_id="O2" value="1.36" spread="1.055"/>
                    <measurement group_id="O3" value="1.38" spread="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.121"/>
                    <measurement group_id="O2" value="1.28" spread="1.031"/>
                    <measurement group_id="O3" value="1.59" spread="1.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Effectiveness</title>
        <description>Treatment effectiveness was assessed with the following scale: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, and 4 = extremely effective.</description>
        <time_frame>Weekly, up to 4 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>12 mcg QD</title>
            <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
          </group>
          <group group_id="O2">
            <title>12 mcg BID</title>
            <description>Up to 24 adolescents (12-17 years of age) and all children (6-11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
          </group>
          <group group_id="O3">
            <title>24 mcg BID</title>
            <description>Adolescents (12-17 years of age)and children (6-11 years of age) who are ≥36 kg body weight</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Effectiveness</title>
          <description>Treatment effectiveness was assessed with the following scale: 0 = not at all effective, 1 = a little bit effective, 2 = moderately effective, 3 = quite a bit effective, and 4 = extremely effective.</description>
          <population>ITT Population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.30"/>
                    <measurement group_id="O2" value="1.6" spread="1.27"/>
                    <measurement group_id="O3" value="1.7" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.28"/>
                    <measurement group_id="O2" value="1.7" spread="1.24"/>
                    <measurement group_id="O3" value="2.0" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.51"/>
                    <measurement group_id="O2" value="1.8" spread="1.31"/>
                    <measurement group_id="O3" value="1.8" spread="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.43"/>
                    <measurement group_id="O2" value="1.8" spread="1.22"/>
                    <measurement group_id="O3" value="1.9" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent AEs: up to 4 weeks plus 7 days (from time of first dose to 7 days post-treatment)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>12 mcg QD</title>
          <description>Children (6-11 years of age) who are at least 12 kg, but less than 24 kg, body weight, and young children (&lt;6 years of age and able to swallow capsules) who are at least 12 kg body weight</description>
        </group>
        <group group_id="E2">
          <title>12 mcg BID</title>
          <description>Up to 24 adolescents (12–17 years of age) and all children (6–11 years of age) who are at least 24 kg, but less than 36 kg, body weight</description>
        </group>
        <group group_id="E3">
          <title>24 mcg BID</title>
          <description>Adolescents (12–17 years of age)and children (6–11 years of age) who are ≥36 kg body weight</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.1</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Clinical Development</name_or_title>
      <organization>Sucampo Pharma Americas, Inc.</organization>
      <phone>301-961-3400</phone>
      <email>info@sucampo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

